PPHM 1501- An open-label, randomized, phase II trial of durvalumab (MEDI4736) with or without bavituximab in patients with previously treated metastatic non-small cell lung cancer (NSCLC): Safety report on first 18 patients.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Cedars-Sinai Medical Center, Sarah Cannon, Providence Portland Medical Center, Moffitt Cancer Center, Emory University, Winship Cancer Institute, Dartmouth–Hitchcock Medical Center, Avid Bioservices (United States), Oncology Specialists of Charlotte, Oncology Hematology Care, The University of Texas Southwestern Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889974834